Still, the company believes the market has room to grow, with only 20 percent of the 3 million Type 1 and insulin taking Type 2
diabetes patients globally using continuous glucose monitors today.
Type 2
diabetes afflicts more than 300 million people
globally, and as many as 15 % of those
patients can not take the first - line therapy metformin because of kidney damage risks.